Ferring to acquire fertility startup Gameto for up to $1.38 billion

Ferring Pharmaceuticals has signed an agreement to acquire Gameto, the fertility startup behind the Fertilo egg maturation therapy, in a deal that could be worth up to $1.3825 billion, the companies said.

Why it matters: The deal would give Ferring the first stem cell derived therapy to reach late stage trials in United States fertility care, a field where treatment still rests on weeks of hormone injections.

Data as of Endpoints News report of October 27, 2026, 09:16 EDT, opened in this run. The article is gated after its first sentence, so the signing of the agreement and the up to $1.3825 billion total are the only deal terms verified here, and no upfront payment, milestone split or closing timetable was available. Single sourced on the deal, grade C. The Fertilo description is from Gameto's own product page. Developing item.

Ferring Pharmaceuticals has signed an agreement to acquire the fertility startup Gameto in a deal that could be worth up to $1.3825 billion, the companies said, according to Endpoints News. No breakdown of upfront and milestone payments was available in the portion of the report that could be read, and no closing timetable was given there.

Gameto’s lead therapy is Fertilo, which uses ovarian support cells derived from induced pluripotent stem cells to mature eggs outside the body, with the aim of improving IVF and egg freezing. The therapy is in a Phase 3 trial in the United States and is already cleared for clinic use in several markets outside the United States.

Ferring to acquire fertility startup Gameto for up to $1.38 billion

Sources